Barclays PLC Oragenics Inc Transaction History

Barclays PLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$0.6 - $0.89 $528 - $783	-880 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$0.52 - $1.52 $457 - $1,337	880 New	880 $1,000
Q3 2020 Nov 12, 2020	SELL	$0.56 - $1.49 $45 - $122	-82 Closed	0 $0
Q2 2020 Aug 12, 2020	SELL	$0.39 - $0.83 $66,477 - $141,478	-170,456 Reduced 99.95%	82 $0
Q1 2020 May 13, 2020	SELL	$0.43 - $0.75 $70,950 - $123,750	-165,000 Reduced 49.17%	170,538 $99,000
Q4 2019 Feb 10, 2020	BUY	$0.42 - $0.62 $14,757 - $21,785	35,138 Added 11.7%	335,538 $175,000
Q3 2019 Nov 14, 2019	BUY	$0.36 - $0.64 $36,000 - $64,000	100,000 Added 49.9%	300,400 $162,000
Q2 2019 Aug 14, 2019	BUY	$0.46 - $0.6 $11,500 - $15,000	25,000 Added 14.25%	200,400 $98,000
Q1 2019 May 15, 2019	BUY	$0.57 - $1.05 $22,799 - $42,000	40,000 Added 29.54%	175,400 $103,000
Q4 2018 Feb 14, 2019	BUY	$0.78 - $3.57 $51,694 - $236,601	66,275 Added 95.88%	135,400 $116,000
Q3 2018 Nov 14, 2018	BUY	$0.38 - $1.42 $20,890 - $78,063	54,974 Added 388.48%	69,125 $79,000
Q2 2018 Aug 14, 2018	BUY	$1.16 - $2.0 $13,852 - $23,884	11,942 Added 540.61%	14,151 $20,000
Q1 2018 May 15, 2018	BUY	$1.6 - $3.17 $3,534 - $7,002	2,209 New	2,209 $4,000

Ticker OGEN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 116,395,000
Market Cap $36.1M
Description
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immuni...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.